QIAGEN to Present at Lehman Brothers 10th Annual Global Healthcare Conference



    VENLO, The Netherlands, March 15 /CNW/ - QIAGEN N.V. (NASDAQ:   QGEN;
Frankfurt, Prime Standard: QIA) today announced that it will present at the
Lehman Brothers Tenth Annual Global Healthcare Conference at 4:45 p.m. EDT on
Monday, March 19, 2007. The conference is being held at Loews Miami Beach
Hotel in South Beach, Florida.
    Roland Sackers, QIAGEN's Chief Financial Officer, will provide an
overview of the company, discuss QIAGEN's business as well as recent
developments and outline future opportunities. QIAGEN's presentation will be
audio webcasted live for investors and available for replay for a period of
90 days following the conference. The presentation can be accessed in the
Investor Relations section at http://www.qiagen.com.

    About QIAGEN:

    QIAGEN N.V., a Netherlands holding company, is a leading provider of
innovative technologies and products for pre-analytical sample preparation and
molecular diagnostics solutions. QIAGEN has developed a comprehensive
portfolio of more than 500 proprietary, consumable products and automated
solutions for sample collection, and nucleic acid and protein handling,
separation, and purification. QIAGEN also supplies diagnostic kits, tests, and
assays for human and veterinary molecular diagnostics. The company's products
are sold to academic research markets, and to leading pharmaceutical and
biotechnology companies; as well as to diagnostics laboratories. QIAGEN also
provides purification and testing solutions to applied testing markets: such
as forensics, animal or food testing, and pharmaceutical process control.
    QIAGEN employs more than 1,900 people worldwide. QIAGEN products are sold
through a dedicated sales force and a global network of distributors in more
than 40 countries. Further information about QIAGEN can be found at
www.qiagen.com.

    Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
Securities Exchange Act of 1934, as amended. To the extent that any of the
statements contained herein relating to QIAGEN's products, markets, strategy
or operating results are forward-looking, such statements are based on current
expectations that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks associated with
management of growth and international operations (including the effects of
currency fluctuations and risks of dependency on logistics), variability of
operating results, the commercial development of the applied testing markets,
clinical research markets and proteomics markets, nucleic acid-based molecular
diagnostics market, and genetic vaccination and gene therapy markets,
competition, rapid or unexpected changes in technologies, fluctuations in
demand for QIAGEN's, products (including fluctuations due to the level and
timing of customers' funding, budgets, and other factors), difficulties in
successfully adapting QIAGEN's products to integrated solutions and producing
such products, the ability of QIAGEN to identify and develop new products and
to differentiate its products from competitors' products, market acceptance of
QIAGEN's new products, the integration of acquisitions of technologies and
businesses, and the timing of product introductions by our commercial
partners. For further information, refer to the discussions in reports that
QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange
Commission (SEC).





For further information:

For further information: Dr. Solveigh Mahler, Director of Investor
Relations, QIAGEN N.V., +49-2103-2911-710, e-mail:
solveigh.maehler@QIAGEN.com

Organization Profile

QIAGEN N.V.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890